BELLEVUE, Wash.–(BUSINESS WIRE)–Cardiac Insight, Inc., a leading healthcare innovator specializing in prescription-based wearable cardiac sensors and automated electrocardiogram (ECG) analysis software for cardiac arrhythmia diagnosis, has been named a finalist in the 2022 Fierce Healthcare Innovation Awards for its Cardea SOLO™ ECG System. The awards recognize innovations that are transforming the healthcare […]
Author: Ken Dropiewski
Aidoc expands cardiology solutions by bringing Us2.ai’s echo AI into proprietary operating system
Aidoc’s aiOS™ offers clinicians access to real-time data and insights, helping to provide streamlined end-to-end patient care management. NEW YORK, Oct. 20, 2022 /PRNewswire/ — Aidoc, the leading provider of healthcare AI solutions, announced today a partnership with Us2.ai to bring its FDA-cleared and CE Marked AI algorithm to analyze and interpret echocardiograms […]
SIRONA completes enrollment – A leap in the DCB treatment of femoropopliteal arterial disease
TAMPA, Fla., Oct. 21, 2022 /PRNewswire/ — Concept Medical Inc. announces the successful completion of the SIRONA – World’s first and the largest head-to-head RCT investigating the use of Sirolimus Drug Coated Balloon (DCB) (Magic Touch PTA – Concept Medical Inc.) V/S Paclitaxel DCB angioplasty for the treatment of peripheral artery disease in the femoropopliteal […]
Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors
Lars Ekman and Patrick O’Sullivan to Retire from Amarin Board at year-end New Independent Directors Bring Significant International Experience in Healthcare and Finance Seventy-five Percent New Independent Directors Appointed Over Last Twelve Months Amarin Continues Active Board Refreshment Program DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) — […]
CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research
WALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research. The publication includes clinical data from the company’s randomized, Phase […]
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
U.S. FDA has assigned a target action date of June 16, 2023 Application based on results from the Phase 3 VALOR-HCM study PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) for CAMZYOS® (mavacamten) for an […]
Catheter Precision Expands U.S. Customer Base for VIVO™ for Non-invasive Arrythmia Location Detection Before Ventricular Ablation Procedures
MT. OLIVE, N.J. & CARLSBAD, Calif.–(BUSINESS WIRE)–Catheter Precision, Inc. (“Catheter Precision”), a medical device company focused on cardiac electrophysiology, announces receipt of three commercial orders in the past 60 days as usage of the device continues to increase in the U.S. On September 12, 2022 privately held Catheter Precision announced […]
HeartSciences Named as a Top 10 MedTech Startup 2022 by MedTech Outlook Magazine
Southlake, Texas, Oct. 20, 2022 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today announced it was recognized by MedTech Outlook […]
Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) announces the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps. The FDA’s action is another affirmation that Impella heart pumps are safe and effective for cardiogenic shock, high-risk PCI, post-cardiotomy cardiogenic […]
ELEVATE IDE Study highlights the Safety and Effectiveness of the ALTO® Abdominal Stent Graft System in One-year Results; Data to Be Presented at 2022 VEITHsymposium
The Endologix ALTO Stent Graft System treats abdominal aortic aneurysms (AAA) with a success rate of 96.7% at 12 months as observed in ELEVATE IDE Study IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies for the interventional treatment […]



